R-Pharm – Russian high-tech pharmaceutical enterprise, fully vertically integrated specialty care company, which introduces comprehensive solutions for the healthcare system and focuses on R&D, manufacturing and commercializing differentiated pharmaceutical treatments, laboratory equipment and medical devices.
From the beginning, R-Pharm’s goal has been to take on tough health challenges, developing new treatment methods for socially significant diseases, which cause enormous damage to entire modern society and require higher expenses for prevention, treatment and rehabilitation. R-Pharm is advancing life-changing medicines for people living with inflammatory and autoimmune diseases, including a portfolio of products across rheumatological and cardio-vascular diseases.
Key molecules in the portfolio are Olokizumab – a novel IL-6 inhibitor confirmed being effective in a large Phase III clinical program in rheumatoid arthritis and Goflikicept – anti-IL-1 fusion protein, registered for idiopathic recurrent pericarditis. Clinical trials in additional indications are currently ongoing.
R-Pharm is committed to make a lasting impact on the lives of patients suffering from a broad range of immune-mediated inflammatory diseases.
